Par inks $410M deal for niche generics maker Anchen

Par Pharmaceutical ($PRX) is adding to its stable of generic meds with a $410 million buyout. The deal with Anchen Pharmaceuticals will bring 5 marketed products and another 27 awaiting approval from FDA. Privately held, Anchen focuses on extended release generics and niche knockoff drugs, the company said in a statement.

Based in Irvine, CA, Anchen expects to launch 8-10 generics over the next two years, Par said, and 5 of its pending FDA apps cover drugs that are believed to have first-to-file status--and the coveted 180-day exclusivity that goes along with it.

But Anchen's attractions aren't just its products. The company's manufacturing capacity and "state-of-the-art equipment," not to mention R&D capabilities, are key to the deal, too. All this, "combined with Par's existing capabilities and pipeline, more than doubles our product opportunities," CEO Patrick LePore said in a statement.

The deal will be financed with cash on hand, plus a $350 million loan. Par expects Anchen to add to earnings immediately. It's the company's second buyout this year, Reuters notes, after a $37.6 million deal to buy India's Edict Pharmaceuticals.

- see the release from Par
- get more from Reuters

Suggested Articles

While the failure might be a missed chance at revenue, it shouldn’t hurt Ibrance’s ability to rack up sales in the metastatic setting, one exec says.

Patients receiving Bavencio actually did worse than those who got placebo, increasing the risk of death by 31%.

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.